Research programme: fatty acid amide hydrolase modulators - Evotec SE
Alternative Names: RN-A; RN-BLatest Information Update: 26 Sep 2019
At a glance
- Originator Renovis
- Developer Evotec SE
- Class
- Mechanism of Action Fatty acid amide hydrolase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in Germany
- 01 Dec 2008 Pharmacodynamics data from a preclinical trial in Neurological disorders presented at the 38th Annual Meeting for the Society of Neuroscience (SfN-2008)
- 03 May 2008 Renovis has been acquired by Evotec AG